Definitive radiotherapy is one of the important methods for inoperable locally advanced lung cancer. The recommended dose for definitive radiotherapy is 60-70Gy, and the optimal dose is still uncertain. Residual lesion after radiotherapy is a risk factor for recurrence. High doses to targeted tumor areas can effectively improve the local control rate, while minimizing toxic side effects. The regression pattern of primary lesions in lung caner after radiotherapy has not been clarified. This study intends to retrospectively collect clinical data of lung cancer patients with definitive radiotherapy, and explore the pattern of tumor regression after radiotherapy. It will help optimize the radiotherapy plan for lung cancer, so as to improve the efficacy and prognosis.
This study intends to retrospectively screen and include participants according to inclusion and exclusion criteria, and collect the clinical data of participants by previous medical records. Imaging tools will be used to quantify changes in the spatial location, diameter and volume of target lesions to evaluate tumor regression rate and radiotherapy efficacy, and to explore tumor regression pattern and establish model. In addition, the relationship between tumor regression rate, incidence of adverse radiation events, prognosis and related factors will be analysed.
Study Type
OBSERVATIONAL
Enrollment
500
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
RECRUITINGRenmin Hospital of Wuhan University
Wuhan, Hubei, China
RECRUITINGTumor regression rate
(1- post-treatment tumor volume/baseline tumor volume)×100%
Time frame: Within 1 year after completion of radiotherapy.
Objective response rate
It refers to the proportion of patients who experience a complete or partial remission of tumors in response to treatment, as determined by RECIST criterion.
Time frame: Within 1 year after completion of radiotherapy.
Disease control rate
It refers to the proportion of patients who experience an objective response (complete or partial remission) or stable disease in response to treatment, as determined by RECIST criterion.
Time frame: Within 1 year after completion of radiotherapy.
Progression-free survival
It's calculated from the start of treatment until the time of disease progression or the patient's death, whichever comes first.
Time frame: From the start of treatment until the time of disease progression or death, assessed up to 120 months.
Overall survival
It measures the length of time from the start of treatment until the death of the patient from any cause.
Time frame: From the start of treatment until the time of death, assessed up to 120 months.
Adverse event rate
It refers to the frequency of treatment related adverse event.
Time frame: Within 1 year after completion of radiotherapy.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.